This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Low Glycemic Index Diets (With Pulses) in Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborators:
Saskatchewan Pulse Growers
Pulse Canada
Information provided by (Responsible Party):
David Jenkins, University of Toronto
ClinicalTrials.gov Identifier:
NCT01063361
First received: February 3, 2010
Last updated: December 7, 2015
Last verified: December 2015
  Purpose
Healthy individuals with type 2 diabetes will receive intensive counseling on food selection to improve glucose control using either high cereal fiber dietary strategies or low glycemic index foods emphasizing dried legumes and their products. The treatments will last 3 months with bloods taken for HbA1c, glucose and blood lipids. If the study shows a benefit for either or both diets, then use of high fiber and/or low glycemic index foods in the diet may provide another potential way to improve glucose control and lower cholesterol levels in non-insulin dependent diabetes.

Condition Intervention Phase
Type 2 Diabetes Dietary Supplement: Low glycemic index diet with pulses Dietary Supplement: High Cereal Fibre Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Low Glycemic Index Diets (With Pulses) on Glucose Control in Non-Insulin Dependent Diabetics

Resource links provided by NLM:


Further study details as provided by David Jenkins, University of Toronto:

Primary Outcome Measures:
  • change in HbA1c [ Time Frame: from prestudy and week 0, to end of treatment weeks 8, 10, and 12 ]
  • serum lipids [ Time Frame: from prestudy and week 0, to end of treatment weeks 8, 10, and 12 ]

Secondary Outcome Measures:
  • fasting glucose [ Time Frame: from prestudy and week 0, to end of treatment weeks 8, 10, and 12 ]
  • change in weight, waist and hip circumference [ Time Frame: weeks 0, 12 ]
  • blood pressure [ Time Frame: from prestudy and week 0, to end of treatment weeks 8, 10, and 12 ]
  • creatine, urea, and c-peptides in 24 hour urine collection [ Time Frame: 0, 12 weeks. ]

Enrollment: 131
Study Start Date: February 2010
Study Completion Date: August 2015
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low glycemic Index Diet
Low glycemic Index Diet, emphasizing pulses
Dietary Supplement: Low glycemic index diet with pulses
Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
Active Comparator: High Cereal Fibre Diet Dietary Supplement: High Cereal Fibre
Subjects will be advised to follow a healthy high fibre diabetic diet.

  Eligibility

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Men and women with type 2 diabetes who

  • are treated with oral hypoglycemic agents at a stable dose for at least 8 weeks
  • have a HbA1c in the range of 6.5% to 8.5% at screening and at the visit prior to randomization
  • have diabetes diagnosed >6 months
  • have maintained stable weight for 2 months (within 3%)
  • have a valid OHIP card and a family physician
  • if prescribed lipid medication, have taken a stable dose for at least 2 weeks
  • if prescribed blood pressure medication, have taken a stable dose for at least 1 week
  • can keep written food records, with the use of a digital scale

Exclusion Criteria: Individuals who

  • take insulin
  • take steroids
  • have GI disease (gastroparesis, celiac disease, ulcerative colitis, Crohn's Disease, IBS)
  • have had a major cardiovascular event (stroke or myocardial infarction) in the past 6 months
  • take warfarin (Coumadin)
  • have had major surgery in the past 6 months
  • have a major debilitating disorder
  • have clinically significant liver disease (AST or ALT > 130 U/L), excluding NAFL or NASH
  • have hepatitis B or C
  • have renal failure (high creatinine > 150 mmol/L)
  • have serum triglycerides ≥ 6.0 mmol/L
  • have a history of cancer, except non-melanoma skin cancer (basal cell, squamous cell)
  • have food allergies to study food components
  • have elevated blood pressure (> 145/90) unless approved by GP
  • have acute or chronic infections (bacterial or viral)
  • have chronic inflammatory diseases (e.g. rheumatoid arthritis, lupus; ulcerative colitis)
  • have other conditions which in the opinion of any of the investigators would make them unsuitable for the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01063361

Locations
Canada, Ontario
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Sponsors and Collaborators
University of Toronto
Saskatchewan Pulse Growers
Pulse Canada
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: David Jenkins, Principle Investigator, University of Toronto
ClinicalTrials.gov Identifier: NCT01063361     History of Changes
Other Study ID Numbers: 09-192
Study First Received: February 3, 2010
Last Updated: December 7, 2015

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 27, 2017